Alphanine SD market to grow with hemophilia B demand

The Business Research Company says the global Alphanine SD market is set to expand from 2026 to 2030 as hemophilia B diagnoses rise, prophylactic treatment grows, and surgery-related bleeding management stays in demand. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - The Alphanine SD market is tied to hemophilia B care, so changes in diagnosis rates, treatment access and healthcare spending can directly affect demand. - Growth in clotting-factor therapy use matters because Alphanine SD is used to prevent and control bleeding episodes, including around surgery.

What happened: - The Business Research Company released its Alphanine SD Market Report 2026, covering market size, trends and a global forecast for 2026-2035. - The report says the Alphanine SD market is expected to grow steadily from 2026 to 2030. - North America held the largest share of the global Alphanine SD market in 2025. - Asia-Pacific is forecast to be the fastest-growing region in the coming years.

The details: - Alphanine SD is a high-purity, freeze-dried concentrate of Factor IX derived from human plasma. - The therapy is used to treat hemophilia B by replacing the missing clotting factor. - Alphanine SD is used to control and prevent bleeding, manage bleeding around surgeries and support routine prophylaxis for hemophilia B patients. - Historical market growth was supported by established hemophilia B treatment protocols, availability of plasma-derived clotting factors, hospital reliance for factor replacement therapies, surgical bleeding management needs and proven clinical effectiveness. - The report says future growth will be driven by rising hemophilia diagnosis rates, wider use of prophylactic therapies, more surgical procedures, stable plasma supply and demand in emerging healthcare markets. - The report highlights continued use of plasma-derived clotting factors, stronger demand for hemophilia B prophylaxis, hospital-focused bleeding management, preference for high-purity factor IX products and use in surgical bleeding control as key market trends. - A World Federation of Hemophilia report released in October 2025 said that, as of 2024, 271,918 patients worldwide had been diagnosed with hemophilia. - The same report counted 224,353 Hemophilia A cases and 45,600 Hemophilia B cases. - Rising healthcare expenditure is also supporting market growth. - The UK's Office for National Statistics said in a May 2024 report that total healthcare spending grew 5.6% nominally between 2022 and 2023, compared with 0.9% growth in 2022. - Aging demographics are another driver, because older adults are more likely to need treatment for blood clotting disorders. - The World Health Organization said in October 2025 that by 2030, one in six people worldwide will be aged 60 or older, and by 2050 that population is expected to reach 2.1 billion.

Between the lines: - The report points to a market shaped by both clinical need and healthcare-system capacity, with hospitals remaining central to treatment delivery. - The emphasis on high-purity factor IX and prophylaxis suggests demand is shifting toward more routine, preventive hemophilia B management rather than only crisis treatment. - Broader health spending and aging populations may support demand beyond hemophilia care alone, especially where surgical volume and chronic disease burdens are rising.

What's next: - The report expects continued market expansion through 2030 as diagnosis improves and prophylactic therapy adoption widens. - Emerging healthcare markets and the Asia-Pacific region may become more important growth areas. - More information is available in the full market report and a free sample.